Clinical & Translational Oncology最新文献

{"title":"Correction: Management and outcome of children with high‑risk neuroblastoma: insights from the Spanish Society of Pediatric Hematology and Oncology (SEHOP) neuroblastoma group on refractory and relapse/progressive disease.","authors":"Blanca Martínez de Las Heras, Pedro M Rubio-Aparicio, Alba Rubio-San-Simón, Lucas Moreno, Paula Mazorra, Ricardo López Almaraz, Mercedes Llempén López, Julia Balaguer Guill, Vanessa Segura, Mar Bermúdez, Irene Jiménez, Désirée Ramal, Adela Cañete","doi":"10.1007/s12094-025-03912-2","DOIUrl":"https://doi.org/10.1007/s12094-025-03912-2","url":null,"abstract":"","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143812782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comprehensive clinico-pathological review of a series of pediatric, adolescents and young adults with high-grade osteosarcoma: from clinics to biomarker discovery.","authors":"Susana Buendía-López, Alba Rubio-San-Simón, Jen-Hao Wu, Daniel Azorín-Cuadrillero, Ana Sanz-Miguel, Álvaro Lassaletta, Sara Inmaculada Sirvent-Cerdá, Laura Rey-Portela, Juan Carlos Abril, Lucas Moreno, Luis Madero-López, Javier García-Castro, Francisco Bautista","doi":"10.1007/s12094-025-03901-5","DOIUrl":"https://doi.org/10.1007/s12094-025-03901-5","url":null,"abstract":"<p><strong>Background: </strong>We analyzed clinical and immunohistochemical characteristics of pediatric, adolescents and young adults with high-grade osteosarcoma (HGOS) to validate prognostic factors, identify targetable and prognostic biomarkers and define management of multiple relapses.</p><p><strong>Methods: </strong>Retrospective analysis of 67 patients with HGOS between 2001 and 2020 was studied. BTN3A2, HSP90 and GLYPICAN1 were further analyzed based on their high expression on in silico model.</p><p><strong>Results: </strong>Conventional osteosarcoma was the most frequent histology subtype (89.5%); 26.9% of patients had metastases at diagnosis. Proportion of limb-sparing surgery and R0 resection increased before and after 2011 (66.6% vs. 96.2%; 78.5% vs 87.5% respectively), while no treatment-related deaths occurred after 2011. 5-year OS and EFS were 61% and 56.6%, (5.4-year median follow-up (0.20-17.40). In multivariate analysis, metastatic disease was the sole independent prognostic factor. 5-year EFS and OS for patients with 1st, 2nd, and 3rd relapse were 8-12%, 0-5%, and 11.1-11.1% respectively. BTN3A2 was highly expressed at diagnosis, surgery, and relapse.</p><p><strong>Conclusion: </strong>Metastatic disease remains the most important prognosis factor in HGOS. Improvements in surgical procedures and reduction in treatment-related mortality were observed. Survival after multiple relapses remains poor; we define figures to be used for benchmarking in clinical trials. BTN3A2 is a potential therapeutic target.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143812780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral microbes and gastrointestinal cancers: new strategies and insights.","authors":"Chenlu Huang, Yu Li, Cong He","doi":"10.1007/s12094-025-03891-4","DOIUrl":"https://doi.org/10.1007/s12094-025-03891-4","url":null,"abstract":"<p><p>Gastrointestinal (GI) cancers are among the most prevalent cancers globally and represent a leading cause of cancer-related mortality. A distinctive characteristic of these cancers is their association with the microbes. Gut microbiota dysbiosis is widely recognized as a contributing factor in cancer development. Recent advancements in molecular techniques have increasingly underscored the role of oral microbes in GI cancers, especially colorectal cancer. Oral microbes, transported to the gut via swallowed saliva, have been shown to influence GI health. Both in vivo and in vitro investigations demonstrated the impacts of oral microbes in GI cancers. This review explores the changes in oral microbial diversity and relative abundance in esophageal, gastric and colorectal cancers as well as the underlying mechanisms. These mechanisms include immunomodulation, epigenetics, apoptosis, and others. Among these, immunomodulation stands out due to its close connection with cancer treatment. Finally, we discuss the limitations of the current research and propose new perspectives and directions for future studies.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Landscape and clinical implications of EGFR exon 20 insertions in non-small cell lung cancer patients.","authors":"Mónica Garzón-Ibáñez, Roxana Reyes, Miguel Ángel Molina-Vila, Ivana Gabriela Sullivan","doi":"10.1007/s12094-025-03899-w","DOIUrl":"https://doi.org/10.1007/s12094-025-03899-w","url":null,"abstract":"<p><p>Although most mutations in Epidermal Growth Factor Receptor (EGFR) found in non-small cell lung cancer (NSCLC) patients are targetable drivers, exon 20 insertions (ex20ins) represent a distinct and heterogeneous subgroup with differences in treatment outcomes and prognosis. Next Generation Sequencing (NGS) testing has played a key role in identifying ex20ins and associated co-alterations, enhancing our understanding of the complex biology within this group. Furthermore, new molecules recently developed, some of them still under investigation, are shown promising results in the clinical management of ex20ins patients. This review aims to give an update of the landscape of EGFR ex20ins, focusing on their molecular and clinical implications as well as on new treatment strategies emerging in clinical trials.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low versus null HER2 tumour expression in \"HER2-negative\" breast cancer: long-term outcomes based on phenotypes.","authors":"Israel Barco, Clarisa González, Marc García-Font, Antonio García Fernández, Manel Fraile, Xavier Tarroch, Xavier Morlius, MCarmen Vidal, Sonia González, Claudia B Mitru, Elena Vallejo, Gerard Molina, Marta Torras, Carolina Chabrera","doi":"10.1007/s12094-025-03882-5","DOIUrl":"https://doi.org/10.1007/s12094-025-03882-5","url":null,"abstract":"<p><strong>Background: </strong>Two new categories of breast cancer (BC) have been proposed among HER2-negative patients: HER2 0 + and HER2-low breast cancer. We combined these two categories with Perou's classification. We aimed to identify potential differences in clinicopathological features and prognosis using a new, unofficial classification: Luminal A HER2 0 + , Luminal A HER2-Low, Luminal B HER2 0 + , Luminal B HER2- Low, Triple Negative HER2 0 + , and Triple Negative HER2-Low.</p><p><strong>Patients and methods: </strong>We conducted a retrospective analysis of our database from January 1, 2005, to December 31, 2018. Cox Regression served as the basis for our study.</p><p><strong>Results: </strong>We identified 1704 BC tumor cases from 1,639 HER2-negative patients (65 had bilateral BC). Among these, 608 cases were HER2 0 + , and 1096 were HER2-Low (aggregate). The median follow-up period was 120 months after surgery. None of the patients received anti-HER2 therapy. Case distribution was as follows: Luminal A HER2 0 + : 259. Luminal A HER2-low: 501. Luminal B HER2 0 + : 219. Luminal B HER2-low: 499. Triple-Negative HER2 0 + : 130. Triple-Negative HER2-low: 96. There was a 12.2% excess in the Triple Negative rate in the HER2 0 + group, compared with the HER2 Low group (aggregate), which was highly significant (Chisquare, p < 0.01). Although the HER2 0 + versus HER2 Low Hazard Ratio (HR) for Specific Mortality was of borderline significance:1.39 (IC 1.00-1.92, p = 0.049), the TN imbalance complicated a direct comparison between the two groups. After stratification using the noncanonical classification, the HR was highly significant, but only for the Luminal A subtype: 2.28 (IC 1.09-4.36, p = 0.028).</p><p><strong>Comments: </strong>In the noncanonical classification, the effect of the unbalanced Triple-Negative proportions disappeared, and a significant finding emerged: HER2 0 + status had a negative prognostic influence exclusively in Luminal A patients.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Clinical advances and practice updates in genitourinary cancers: a 2024 review from the multidisciplinary Spanish 'Cambados annual meeting'.","authors":"Ignacio Peláez, Martín Lázaro-Quintela, Daniel Pérez-Fentes, Emilio Esteban-González, Enrique Gallardo, Carlos Álvarez-Fernández, Pablo Álvarez Rodríguez, Urbano Anido-Herranz, Cristina Azpitarte Raposeiras, Ángel Maximino Castro-Iglesias, Ovidio Fernández Calvo, Natalia Fernández Núñez, Alicia Folgar-Torres, Carme García Lorenzo, Aránzazu González-Del-Alba, María José Méndez-Vidal, Aurea Molina Díaz, Ignacio Rodríguez Gómez, Sergio Vázquez-Estévez","doi":"10.1007/s12094-025-03911-3","DOIUrl":"https://doi.org/10.1007/s12094-025-03911-3","url":null,"abstract":"","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex and gender differences in cancer pathogenesis and pharmacology.","authors":"Beatriz Bernardez, Oliver Higuera, Virginia Martinez-Callejo, Ana Cardeña-Gutiérrez, José Antonio Marcos Rodríguez, Ana Santaballa Bertrán, Margarita Majem, Maria-Estela Moreno-Martínez","doi":"10.1007/s12094-025-03894-1","DOIUrl":"https://doi.org/10.1007/s12094-025-03894-1","url":null,"abstract":"<p><p>Sex and gender may influence the epidemiology, pathogenesis, and prognosis of cancer. This narrative review describes sex and gender differences in the epidemiology and pathogenesis of cancer, and how such differences may impact the pharmacodynamics and pharmacokinetics of cancer treatment. For most types of cancer unrelated to reproductive function, incidence is higher in males than in females, except for gallbladder and thyroid cancers, which are much more common in women. Cancer mortality is higher in men than women; women account for a larger proportion of survivors. These differences may be related to biological differences in pathogenesis or differences in behaviors relating to cancer risk or detection. The pharmacokinetics and pharmacodynamics of cancer therapies also differ between sexes due to differences in body composition, physiology, and receptor expression. Overall, sex and gender are essential variables to be considered in research and clinical practice, influencing diagnosis, subtyping (biomarkers), prognostication, treatment, and dosage.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143755769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of psychological intervention on negative emotions, pain, and sleep in patients with advanced colon cancer.","authors":"Gang Wang, Shengjie Pan","doi":"10.1007/s12094-025-03910-4","DOIUrl":"https://doi.org/10.1007/s12094-025-03910-4","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effectiveness of psychological interventions in improving negative emotions, pain, and sleep quality among patients with advanced colon cancer.</p><p><strong>Methods: </strong>From March 2021 to March 2023, a total of 218 patients with advanced colon cancer were selected from the First Affiliated Hospital of Soochow University based on strict inclusion and exclusion criteria. Patients were randomly assigned to either the control group or the observation group (109 patients each) using a random number table. The control group received standard medical care, while the observation group received psychological interventions. Both groups were assessed for anxiety and depression levels [using the Self-Rating Anxiety Scale (SAS) and the Self-Rating Depression Scale (SDS)], sleep quality [measured by the Pittsburgh Sleep Quality Index (PSQI)], pain intensity [using the Visual Analog Scale (VAS)], and overall quality of life. Inter-group comparisons were conducted.</p><p><strong>Results: </strong>Post-intervention assessments showed a decrease in SAS and SDS scores for both groups, with the observation group demonstrating a more significant reduction (P < 0.05). Additionally, the observation group reported significantly lower pain levels (VAS scores) and improved sleep quality (PSQI scores) compared to the control group, along with a markedly higher quality of life as measured by the Quality of Life Core Questionnaire (QLQ-30) (P < 0.05).</p><p><strong>Conclusion: </strong>This study demonstrates that psychological interventions effectively alleviate anxiety, depression, pain, and sleep disturbances in patients with advanced colon cancer, thereby improving their overall quality of life. However, further studies are required to explore the long-term impact on prognosis.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143755773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-related differences in the efficacy and toxicity of cancer treatments.","authors":"Ana Santaballa Bertrán, José Antonio Marcos Rodríguez, Ana Cardeña-Gutiérrez, Virginia Martinez-Callejo, Oliver Higuera, Beatriz Bernardez, Maria-Estela Moreno-Martínez, Margarita Majem","doi":"10.1007/s12094-025-03893-2","DOIUrl":"https://doi.org/10.1007/s12094-025-03893-2","url":null,"abstract":"<p><p>Differences between the biological sexes have long been observed in cancer incidence and prevalence, and in treatment outcomes including efficacy and toxicity. Ideally, there should be sufficient information to improve the individualization of cancer treatment by incorporating sex into treatment decisions. Necessary information should include: the nature and source of these differences; whether inherent to the specific cancer (such as molecular profiles, metabolic behaviors, and immune responses); the pathophysiological mechanisms of the specific cancer; or the pharmacokinetic and pharmacodynamic profiles of different cancer drugs. The influence of gender, which is defined as the sociocultural construct that determines societal norms for males and females, should also be included in personalized decision-making. This review aimed to describe the current evidence on the impact of sex and gender on treatment effects, outcomes, and toxicity profiles in cancer patients. Data for the influence of gender were negligible, whereas clinical studies and meta-analyses in different cancer types have identified differences between males and females in the effectiveness on survival outcomes of immunotherapy, chemotherapy, targeted therapy, and radiotherapy. Similarly, toxicity profiles of different cancer treatments varied between sexes. Based on these observed differences, it seems clear that sex should be included as an important variable when individualizing treatment; however, more research into sex- and gender-related differences in cancer treatment efficacy and toxicity, and the causes for these differences, is required before this can be fully incorporated into individualized treatment programs in real-world clinical practice.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143736173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CDK4/6 inhibitors for metastatic breast cancer in routine clinical practice in Spain: survey of patterns of use and oncologists' perceptions.","authors":"F Moreno, V Iranzo, I Álvarez, A Antón, J I Chacón, J Gavilá, M Martín, P Sánchez Rovira, P Gratal, M J Fernández González, R López","doi":"10.1007/s12094-025-03896-z","DOIUrl":"https://doi.org/10.1007/s12094-025-03896-z","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in routine clinical practice in Spain, as well as the perceptions from oncologists.</p><p><strong>Methods: </strong>A survey was developed by nine oncologists, experts in breast cancer, practising in Spain. Survey responses were collected between July 2022 and April 2023.</p><p><strong>Results: </strong>Fifty-one survey responses were obtained. Most oncologists used CDK4/6 inhibitors in the first line. The first-line endocrine therapy most frequently used was an aromatase inhibitor (endocrine-sensitive disease) and fulvestrant (endocrine-resistant disease). CDK4/6 inhibitors were used for primary or secondary resistance, or visceral disease without visceral crisis. A lower-than-standard starting dose was considered (57% of respondents) for specific profiles. Strategies to manage toxicity included switching to another CDK4/6 inhibitor or delaying the next dose. CDK4/6 inhibitors were mostly considered to improve quality of life.</p><p><strong>Conclusions: </strong>Use of CDK4/6 inhibitors in Spain follows current recommendations and aligns with the evidence.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143722570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}